# Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics

> **NCT00375011** · — · TERMINATED · sponsor: **Meridian Bioscience, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Cirrhosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00375011
- **Lead sponsor:** Meridian Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** —
- **Final completion:** 2011-10
- **Target enrollment:** 200 (ESTIMATED)
- **Why stopped:** Company restructured and protocol restructured. Resubmitted with IDE approval under new company name-Exalenz
- **Last updated:** 2022-12-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00375011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00375011, "Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00375011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*